Abstract
A meta-analysis was conducted to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications. We searched PUBMED, EMBASE and the Cochrane Library through June 2016 to identify randomized controlled trials of bevacizumab and wound-healing complications. Seven RCTs studies involving 5,147 participants were included in the analysis. Compared with routine therapy, bevacizumab increased the incidence of wound-healing complications for various cancers. The pooled estimate of odds ratio (OR) was 2.32, and the 95 % confidence intervals (CI) was 1.43 to 3.75. (P < 0.001). Subgroup analyses revealed the similar result in colon carcinoma patients. In conclusion, bevacizumab increases the incidence of wound-healing complications for cancers especially for colon neoplasms patients. However, the adverse effect is not appeared in breast cancer, metastatic renal cell carcinoma, non-small-cell lung cancer and gastro-oesophageal adenocarcinoma. Due to the findings relying chiefly on data from single or two studies, hence, further research is required to assess the wound-healing complications risk of bevacizumab in each oncological indication.
Highlights
As an anti-VEGF monoclonal antibody, bevacizumab (Avastin) was approved for treatment of metastatic colorectal cancer, metastatic breast cancer(MBC), metastatic non-small cell lung cancer (NSCLC), metastatic renal cell cancer (RCC), and glioblastoma multiforme (GBM) by the Food and Drug Administration [1]
To provide the latest and most convincing evidence, we conducted this meta-analysis to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications
The results revealed that bevacizumab might be increased risk of woundhealing complications in patients with a variety of tumors
Summary
As an anti-VEGF monoclonal antibody, bevacizumab (Avastin) was approved for treatment of metastatic colorectal cancer (mCRC), metastatic breast cancer(MBC), metastatic non-small cell lung cancer (NSCLC), metastatic renal cell cancer (RCC), and glioblastoma multiforme (GBM) by the Food and Drug Administration [1]. According to the current point of view, the mechanism of bevacizumab for tumor growth and progression included (1) inhibiting the growth of new vessels (GBM) [3], (2) regression of newly formed vasculature (mCRC) [4], (3) altering vascular function and tumor blood flow (normalization of the vasculature to transiently improve the delivery of and increase the efficacy of cytotoxic agents) (RCC) [5], and (4) direct effects on tumor cells (MBC) [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
